Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024

SELL
$3.19 - $5.32 $319 - $532
-100 Reduced 25.0%
300 $1,000
Q4 2023

Feb 14, 2024

SELL
$1.28 - $3.32 $1,664 - $4,316
-1,300 Reduced 76.47%
400 $1,000
Q3 2023

Nov 14, 2023

BUY
$2.0 - $3.23 $3,200 - $5,168
1,600 Added 1600.0%
1,700 $3,000
Q2 2023

Aug 14, 2023

SELL
$2.91 - $3.53 $5,820 - $7,060
-2,000 Reduced 95.24%
100 $0
Q1 2023

May 15, 2023

SELL
$3.4 - $5.11 $680 - $1,022
-200 Reduced 8.7%
2,100 $7,000
Q4 2022

Feb 14, 2023

BUY
$4.84 - $11.58 $11,132 - $26,634
2,300 New
2,300 $11,000

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $94.2M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.